Objectives: This study investigated whether Env-mediated fusion levels of R5X4 viruses are associated with long-term survival of an infected CCR5À/À patient.
Introduction

HIV type 1 (HIV-1) utilizes CD4
þ as a primary receptor, and either CCR5 and/or CXCR4 as coreceptors to infect susceptible target cells [1] . R5 viruses primarily use CCR5 as a coreceptor, whereas X4 viruses use CXCR4. R5X4 viruses are dual-tropic and can utilize both coreceptors. R5 strains predominate in early stages during the asymptomatic phase of a subtype B infection, whereas X4 or R5X4 strains can emerge late during the symptomatic phase and are often associated with rapid disease progression.
HIV-1 envelope (Env)-mediated membrane fusion activity is achieved by binding of the Env glycoproteins to CD4
þ and a coreceptor on the surface of target cells [2] . The Env consists of two noncovalently associated subunits derived by proteolytic cleavage of the gp160 biosynthetic precursor: the gp120 external subunit, which is responsible for binding to specific target cell receptors, and the gp41 transmembrane subunit, which catalyzes the fusion reaction and anchors Env to the viral membrane. Biochemical, genetic, immunochemical, and structural analyses have implicated the sulfated Nterminus and the second extracellular loop of CCR5; on the gp120 side, the bridging sheet and third variable (V3) loop are directly involved. The V3 loop largely determines the coreceptor usage phenotype (R5, X4, R5X4) [2] .
Homozygosity for a 32-bp deletion in CCR5 (CCR5D32) is highly associated with protection against HIV-1 infection [3] [4] [5] [6] [7] . Although rare, HIV-1 infection of individuals homozygous for the CCR5D32 allele (CCR5À/À) has been previously reported [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . All but two of the reported cases showed exclusive use of CXCR4 by virus isolates or the presence of Env sequences typical of CXCR4-using viruses was observed. Despite the lack of CCR5, some of these infected individuals harbored dual tropic R5X4 viruses [10, 11, 18] , suggesting that there is no selection against the loss of CCR5 usage.
Previous studies investigating the tropism of the infecting viruses focused on sequence analysis of the gp120 subunit of the HIV-1 Env and in particular the V3 loop region. None of the previous studies examined the sequence of the gp41 subunit of the Envs cloned from these infected CCR5À/À individuals. Infected CCR5À/À individuals harboring X4 viruses are characterized with rapid CD4 T-cell loss and disease progression. However, this is not the case when the infecting viruses are dual tropic R5X4 HIV-1 [10, 11, 18] . Churchill et al. [19, 20] reported a nef/LTR deleted R5X4 HIV-1 variant in a slow progressor. Previous studies on long-term nonprogression proposed several factors to account for slow disease progression. Unusual polymorphisms were reported in several HIV-1 genes including Gag, Env, and Nef in eight long-term nonprogressors (LTNPs) [21] . These studies concluded that other viral factors are likely to contribute to modulating the in-vivo pathogenicity of HIV-1 strains with nef/LTR deletions.
To determine whether the long-term survival of DR is associated with other factors related to viral entry, the current study analyzed the Env fusion isolated from two infected CCR5À/À patients harboring R5X4 viruses. Envs were cloned from the DR patient 12 years following primary R5X4 infection and the other 1 year after primary infection [10, 11] . A number of unique polymorphisms were identified across the gp41 subunit that were associated with significant differences in Envmediated fusion activity and delayed onset of syncytia formation. The different fusion phenotypes were confirmed by the transfer of the fusion phenotype upon swapping the sequences encoding the gp41 subunits. The study concludes that the low Env-mediated fusion level of DR is an important factor among others associated with slow disease progression and/or long-term survival in this CCR5À/À patient. The  HeLa,  3T3.T4,  3T3.T4.CXCR4 , and 3T3.T4.CCR5 cell lines were obtained from the NIH AIDS Reagent and Reference Program. All cell lines were maintained in Dulbecco Modified Eagle Medium (DMEM; Quality Biologicals, Gaithersburg, Maryland, USA) containing 10% fetal bovine serum (FBS), 2 mmol/l glutamine, and 2 mmol/l penicillin-streptomycin.
Material and methods
Cells and other reagents
Infected patients with homozygosity for the CCR5D32 allele Patient DR is a homosexual CCR5À/À male with a history of injecting drug use and first tested seropositive for HIV-1 in September 1991 [11] . The DR HIV-1 Envs were cloned directly from blood taken 12 years after patient DR was first tested positive for HIV-1. Patient C2 is another infected CCR5À/À homosexual individual. The clinical history of patient C2 has been previously described [10] . The virus isolate used to clone the C2 Env was obtained from peripheral blood drawn approximately 1 year after the primary infection. The clinical history of C2 revealed high-risk sexual exposure with two to six male partners during every 6-month interval between visits to the clinic [10] .
Sequence determination and analysis
The Consensus Clade B was obtained from the LANL HIV Sequence Database (http://www.hiv.lanl.gov/). The complete gp41 regions of the DR and C2 clones were sequenced using the capillary sequencing at Functional Biosciences Inc. (Madison, Wisconsin, USA). The complete gp41 sequences were constructed using the CAP3 webpage [22] and manual trimming. The sequences were then translated into predicted amino acids, aligned using Clustal W [23] , and then displayed by EMBOSS show align [24] . Determination of the HR2 region's net charge was done by using the ExPASy server's ProtParam [25] . A BLAST search of the HIV Sequence Database was performed with the HR2 region and flanking sections to identify homologous sequences.
Construction of hybrid C2 and DR8 Envs
The C2 and DR8 hybrid Envs were constructed by exchanging most of the gp41 region. C2-22, and DR Env clones were digested with BbvC1 enzyme and swapped the 810-bp fragment, which includes both gp41 HR1 and HR2 regions. The resulting recombinant Envs containing the swapped domains were sequenced and confirmed for the presence of the swapped gp41 region. The V3 swapped mutants were constructed by Mutagenix (Grand Island, New York, USA). The resulting recombinant Envs containing the swapped domain were sequenced and confirmed for the presence of the swapped V3 domain.
Env-mediated fusion and detection of syncytia formation All Env-mediated fusion assays described in this study were conducted as previously described [26, 27] . All Envs were cloned under early/late vaccinia promoter. Effector Hela cells were transfected with 5ug Env-expressing plasmid. Env expression was activated by infecting transfected cells with PT7-lacZ vaccinia virus (lacZ reporter gene under T7 promoter). The target NIH 3T3-CD4, 3T3-CD4-CXCR4, 3T3-CD4-CCR5 cells were infected by vaccinia virus encoding the bacteriophage T7 RNA polymerase. The pSC-59 plasmid encoding an uncleaved Env was used to measure the nonspecific background in the fusion assay. After 1 h of infection at 378C and incubation at 318C for 16 h, the Env-expressing Hela cells were mixed with the target cells at 1 : 1 ratio. The cell mixtures were incubated for the indicated times (60, 90, or 150 min) at 378C and syncytia monitored using an EVOS core XL phase contrast microscope at the same time another portion of the same fusion mix was lyzed by 10% NP-40 and the substrate chlorophenolredb-D-galactopyranoside (CPRG) was added. The VersaMax microplate spectrophotometer (Molecular Devices, San Jose, California, USA) was used to measure the extent of Env-mediated fusion over time with multiple readings taken at regular intervals at a wavelength of 590 nm. Values are reported as optical density (ODX1000/min).
T20 was added at increasing concentrations to the Envexpressing cells before they were mixed with 3T3.T4.CCR5 or 3T3.T4.CXCR4 target cells. The blocking activity of T20 was analyzed by measuring the extent of b-galactosidase produced at each T20 concentration.
Single-round infection assays HIV-1 pseudotyped viral stocks were prepared as previously described [28] . Producer 293T cells were transfected with HIV-LucþEnvÀ and another plasmid DNA containing the desired HIV-1 Env under cytomegalovirus (CMV) promoter. Pseudotyped viral particles were harvested from the culture supernatants after 60-72 h and tittered by measuring the amount of p24 gag viral antigen. Pseudotyped virus infection of either 3T3.T4.CCR5 or 3T3.T4.CXCR4 was performed in 48-well culture dishes (5 Â 10 4 cells/well) at 50 ng of P24-normalized virus. The infections were incubated for 36-40 h at 378C with 5% CO 2 . Infectivity was evaluated by measuring luciferase production. Total cell lysates of DR or C2-expressing cells were used for the western blot analysis. Cells were resuspended in protein lysis buffer (300 mmol/l NaCL, 50 mmol/l Tris-HCL, pH 7.6, 0.1% SDS, Aprotonin 10 mg/ml, PMSF 1 mmol/l) and fractionated in an 8% SDS-PAGE ($0.1 Â 10 6 cells/lane) and transferred into PVDF membrane blots. The blots were reacted with goat antigp120 polyclonal antibodies (AIDS Reagent Program, Germantown, Maryland. USA). Env proteins were visualized using horseradish peroxidase-conjugated antigoat immunoglobulin G antibodies (Santa Cruz Biotech., California, USA) and SuperSignal enhanced chemiluminescence (GE Healthcare, Chicago, Illinois, USA).
Results
Isolation, sequencing, and expression of cloned DR and C2 Envs Sequencing of the gp41 regions of the eight Env clones demonstrated significant polymorphisms in comparison to the consensus gp41 sequence. Significant polymorphisms were observed in the HR1, HR2 domain; however, scattered polymorphisms were also observed in other gp41 regions (Fig. 1 ). The gp41 region had an insertion of the amino acids STNIP found before the HR2 region in the DR Env clones (Fig. 1) . The clade B consensus sequence and the C2 clones have a net charge of À7 based on the simple addition of positive and negative charges of the amino acids within the HR2 region. The DR1, DR8, and DR17 HR2 regions have a lower net negative charge of À3, whereas DR19 has a net charge of À2. This difference in the net negative charge of the HR2 region is due to an increase in the number of positively charged amino acids along with a decrease in the number of negatively charged amino acids in the HR regions of DR clones. Therefore, the net charge of the HR2 domains of the C2 Envs is significantly higher than the corresponding HR2 domains of the DR Envs. It is also noted that all DR clones were missing a methionine residue in the fusion peptide and had a proline instead of the glycine found in all C2 Env clones (Fig. 1 , fusion peptide region).
DR Envs show significantly lower fusion levels in cell fusion and pseudotyped virus infection assays An experimental approach that involves the analysis of fusion between two distinct cell populations was used to compare Env-mediated fusion levels; one expressing CD4 þ (endogenous or vaccinia virus encoded) and the other expressing the indicated HIV-1 Env (vaccinia virus encoded). Fusion was scored by a reporter gene activation assay in which the cytoplasm of one cell population
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FACS analysis of DR and C2 transfected HeLa cells gated on live cells demonstrated comparable cell surface protein expression levels of all Env proteins (Fig. 2b) . Western blot analysis was performed to confirm the proper cleavage of Envs (Fig. 2c) . The results show that the higher Env-mediated fusion activity of the C2 Envs is not due to either cleavage efficiency or Env expression levels.
A single-round infection assay was used to determine the infectivity of the DR and C2 pseudotyped viruses. DR infectivity was significantly lower than reference 89.6 or C2 Envs as measured by luciferase activity (Fig. 2d) larger size syncytia were consistently observed with the C2 Envs at 90 min (Fig. 1e Suppl, http://links.lww.com/ QAD/B329) and 150 min (Fig. 1f , Suppl, http:// links.lww.com/QAD/B329) after cell mixing. Similar results were obtained when 3T3.T4.CXCR4 cells were used as the target cells (data not shown). These results suggested that the higher fusion mediated by the C2 Envs could be due to the earlier onset and larger size of syncytia. The b-galactosidase activity of the same fusion mixtures was measured at the same time the photos were taken to confirm the cell fusion observed in the photomicrographs. The fusion activity levels correlated with the observed number and size of syncytia (Fig. 1g-i , Suppl, http:// links.lww.com/QAD/B329).
The DR and C2 Envs show different sensitivities to the fusion inhibitor T20 T20 blocking experiments were performed to determine whether the polymorphic gp41 sequences impact the inhibition concentration 50 (IC50) of Env-mediated cell fusion. This assay is dependent on measuring the T20 blocking activity at different time points after mixing the Env-expressing and target cells. FACS analysis confirmed comparable cell surface expression of C2 and DR Env proteins in transfected/infected cells.
T20 treatments determined that the IC50 of the C2 Envs ranged between 0.05 and 0.1 mg/ml (Fig. 3a and c) . The IC50 for the DR Envs was at least 10 times higher and ranged from 1.0 to 1.1 mg/ml (Fig. 3b and d) . The results indicate a significant difference between the C2 and DR Envs in terms of their sensitivity to the fusion peptide mimic T20.
Swapping the gp41 subunits, but not the V3 domain, results in the transfer of the Envmediated fusion phenotype To determine whether the gp41 polymorphisms had an impact on the Env fusion activity, we next tested whether swapping the polymorphic g41 subunit or V3 domain would result in gain or loss of Env-mediated fusion activity (Fig. 4a) . The fusion results demonstrated that the hybrid Envs with the swapped gp41 subunit showed the transfer of the fusion phenotype. For example, compared to the parental DR Env, the DR Env containing the C2-22 gp41 region showed higher Env-mediated fusion activity (Fig. 4b) . In contrast, compared to the parental C2-22 Env, the C2-22 Env containing the DR gp41 region showed lower fusion activity (Fig. 4b) . In contrast, swapping the V3 domains did not result in a significant change in the Env fusion phenotype (Fig. 4b) . T20 was added at increasing doses to Env-expressing cells prior to cell mixing to confirm the transfer of the fusion phenotype by the swapped gp41 Envs. The results indicated that the IC50 of the swapped Envs correlated with the source of the gp41 region (Fig. 5) . For example, the IC50 of C2 Env containing the DR gp41 (C2-DR8gp41) was at least 10 times higher than the IC50 of the parental C2-22 Env (Fig. 5a and c) . In contrast, the IC50 of the DR Env containing the C2-22 gp41 region was lower than that of the parental DR8 Env (Fig. 5b and  d) . The results indicated that the sensitivity to T20 was transferred by swapping the gp41 regions provided further evidence for the distinct fusion phenotypes of C2 and DR Envs and confirmed DR's low Env fusion phenotype.
Discussion
The study reports novel gp41 subunit sequences derived from eight R5X4 Env glycoproteins cloned from two CCR5À/À individuals (C2 and DR). We demonstrated that the gp41 polymorphisms of two infected CCR5À/À patients translated into two distinct fusion phenotypes. The observed gp41 polymorphisms were not associated with resistance to fusion inhibitors because the patients were naïve for enfuvirtide therapy [11] . The low Envmediated fusion phenotype is associated with DR Envs, derived from a chronically infected patient who is a longterm survivor. The observed significant differences in the Env-mediated fusion activities were not due to differences in Env expression or processing because all Envs were comparably expressed at the cell surface demonstrated by FACS analysis using monoclonal antibodies to gp120. The Env-mediated fusion results reported in this study are different from those previously published by Gray et al. [11] . This is due to differences in the experimental make-up, including plasmid vector backbones, target cell lines, Target-to-Env ratio, and incubation periods of the Env fusion mix. For example, Gray et al. incubated the Env fusion mix overnight, whereas the current study incubated the fusion mix for a maximum of 2.5 h. In addition, they used a 10 : 1 targetto-Env ratio, whereas our assay used 1 : 1 ratio. In pseudotyped virus infections, they used cf2 cells and measured luciferase at 72 h postinfection, whereas this study used 3T3.T4 cells and measured luciferase at 36-40 h postinfection.
A BLAST search of the STNIP and the gp41 region of the DR Env clones returned three hits (87-96% identical) of three progressors: HIV Sequence Database loci AF042105.1, AF042102.1, and AF042106.1. Like DR these also had a net charge of À3, and another hit (92% identical) of HIV-1 sequences from four members of the Sydney Blood Bank Cohort of long term nonprogressors (AAD03239.1). The BLAST search also returned another two hits (91% identical) of two isolates, one from an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients [30] , and another from an impaired fitness study of acute/early viruses in persons who became HIV controllers. These hits were not returned when the BLAST search was performed using the C2-22 gp41 sequence. In contrast, a BLAST search of the gp41 region of the C2 Env clones returned different hits (93% identical) of HIV-1 Envs that are consistent with more pathogenic viruses, HIV Sequence Database loci U69593.1 [31] , L02317.1 [32] , and HQ699978.1 [33] . Similar to the DR and C2 polymorphisms concentrated in the HR2 region, previous studies reported unusual polymorphisms in the gp41 regions of eight LTNPs with a significant number occurring in the HR2 region [21] . The V3 loop of HIV-1 gp120 has been intensively studied to analyze interactions with the coreceptors and predicting coreceptor usage of HIV-1 isolates [34] [35] [36] [37] . Because both DR and C2 Envs are R5X4 swapping the V3 loop did not result in a significant change in Env fusion. We used the V3 swapping as a control to confirm the distinct Env fusion phenotypes of DR and C2. As expected, the V3 loop swap did not significantly change the T20 IC50 of Env fusion. However, swapping the gp41 regions of DR and C2 resulted in the transfer of the T20 IC50, indicating two distinct fusion phenotypes. Previous studies have demonstrated the importance of the HR domain in Env fusion kinetics. Sivaraman et al. [38] demonstrated that the heptad repeat 2 domains is the major determinant for enhanced HIV-1 fusion and pathogenicity. Other studies demonstrated that enfuvirtide-resistant HR2 polymorphism N140I combined with the HR1 V38A mutation is associated with a less cytopathic phenotype [39] . It is possible that the higher net negative charge of the HR2 domain of the C2 Envs is associated with these observed functional differences. The higher negative charge may promote better interaction of the HR2 domain with the host cell membrane, leading to higher Env-mediated fusion signals.
Previous studies by Shioda et al. [40] have suggested the association of V2 extensions with slow disease progression. Other studies by Wang et al. indicated that HIV-1 strains from a cohort of American patients showed a V2 region extension unique to slow progressors and LTNPs [41] . The DR V2 extension introduced four new Nlinked glycosylation sites in the gp120 subunit [11] . It has previously been demonstrated that V1-V2 loop sequences expand and add glycosylation sites over the course of infection, and that these modifications affect antibody neutralization sensitivity [42] . Sagar et al. [42] suggested that changes within the V1-V2 domains over the course of infection might impact host/receptor/ coreceptor interaction. Hybrid Envs containing swapped V2 domains might provide an insight into the role of the V2 extension in Env-mediated fusion activity.
It is also possible that viral adaptation to grow in CCR5À/À cells resulted in polymorphisms that favor slow disease progression in some of the patients harboring R5X4 viruses. The in-vivo importance of CCR5 density in determining viral load has previously been established. Reynes et al. [43] postulated that CCR5 expression affects virus production and viral load, and found a strong correlation between CCR5 density and viral load. Platt et al. [44] elucidated a threshold of 10 000 CCR5 molecules per CD4 þ cell as a requirement for HIV infection. Most individuals with a low viral load have CCR5 densities below this value [43] . The persistence of R5 viruses in a CCR5-deficient patient suggests that structural features of Env associated with CCR5 usage may allow HIV-1 persistence through a non-CCR5-dependent mechanism. It will be interesting to investigate whether similar fusion phenotypes can be isolated from CCR5þ/þ patients.
